An interventional study of Supervised Progressive Resistance Training and Standard Lifestyle Advice in Sarcopenic Obesity, Obesity & Overweight and Insulin Resistance Syndrome, sponsored by Diabetes Foundation, India. Not yet recruiting at 1 site in India. Open to participants aged 35 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Diabetes Foundation, India · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Obesity with a site in India — 25 open to participants now, 32 under way, 23 of them phase 3. Obesity · India.
Among the 78 studies in Obesity with a site in India, this one is the 47th largest by planned enrollment of the 69 interventional ones that give a count, is one of 19 that started in 2026, is one of 20 with no phase, reaches primary completion later than 28 of the 31 other live ones, and was the 74th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →25 of the 78 studies in Obesity with a site in India are open now. Recruiting first, the newest first:
AstraZeneca · Sites in India, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in India, United States, Argentina and 13 more countries
Ages 18+
All India Institute of Medical Sciences, Bhubaneswar · Sites in India
Ages 18–60
JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH · Sites in India
Ages 20–60
Novo Nordisk A/S · Sites in India, United States, Argentina and 24 more countries
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 35 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 731 across the 69 interventional studies, 1,224 across the 9 observational. Of the 40 that completed or were terminated, 11 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 78 have an industry lead sponsor. The 10 most frequent:
Diabetes Foundation, India is the lead sponsor of 31 studies on the registry; 15 are open to participants now.
Diabetes Foundation, India has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity with a site in India that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies in Obesity with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates whether a 12-month supervised progressive resistance training program improves lean body mass and metabolic health in obese North Indian adults aged 35-60 years. Asian Indians are uniquely predisposed to sarcopenic obesity-the coexistence of excess body fat and reduced muscle mass-which significantly increases the risk of type 2 diabetes and cardiovascular disease.
Participants will be stratified into High-Ratio and Low-Ratio groups based on their baseline Myostatin/Follistatin (MSTN/FST) ratio, an biological index of muscle catabolism versus growth. Half of the participants in each stratum will undergo a 12-month supervised resistance training program, while the other half will receive standard lifestyle advice. The primary goal is to determine whether baseline MSTN/FST ratio predicts the extent of muscle mass gain and whether reducing this ratio mediates improvements in insulin resistance and systemic inflammation.
Background \& Scientific Rationale: Sarcopenic obesity is a major driver of cardiometabolic risk in Asian Indians due to low baseline lean mass combined with high visceral adiposity. Myostatin (MSTN) acts as a primary negative regulator of muscle growth, whereas follistatin (FST) acts as its circulating antagonist. Previous genetic research demonstrates that gain-of-function Myostatin gene variants are strongly associated with lower lean body mass and increased adiposity in North Indians. This trial prospectively tests whether the serum MSTN/FST ratio functions as a precision biomarker to stratify exercise response and guide targeted exercise interventions.
Study Objectives:
Determine the efficacy of a 12-month supervised resistance training program on total lean body mass (LBM) and physical performance compared to lifestyle control, testing for treatment interaction across baseline MSTN/FST strata.
Characterize the molecular adaptations of the myostatin axis by measuring serum myostatin, follistatin, MSTN/FST ratio, and peripheral blood mononuclear cell (PBMC) MSTN mRNA expression at baseline and 12 months.
Assess whether reductions in the MSTN/FST ratio mediate improvements in insulin resistance (HOMA-IR), systemic inflammatory markers (IL-6, TNF-α, hsCRP), and muscle quality.
Trial Design \& Interventions: A single-center, ratio-stratified, 1:1 parallel-group randomized controlled superiority trial of 200 obese North Indian adults.
Resistance Training Arm (n=100): 3 supervised sessions per week (60 minutes per session) at 70-80% 1-repetition maximum (1RM) using progressive resistance overload reassessed every 8 weeks.
Control Arm (n=100): Standard individualized dietary and physical activity advice per national guidelines without supervised exercise sessions.
Outcome Assessments: Dual-energy X-ray absorptiometry (DEXA) for total LBM, appendicular lean mass, and body fat percentage; handgrip dynamometry and 1RM testing for strength; quantitative ELISA for serum biomarkers; real-time qRT-PCR (2-ΔΔCt method) for PBMC MSTN mRNA expression; and standardized biochemical panels for glycemic and inflammatory profiles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Supervised progressive resistance training program consisting of 3 sessions per week for 12 months (60 minutes per session) at 70-80% 1-repetition maximum (1RM). Includes multi-joint upper and lower body exercises (leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest/overhead press, crunches) with formal load reassessment every 8 weeks.
Behavioral: Supervised Progressive Resistance Training · Behavioral: Standard Lifestyle Advice
A single structured 60-minute lifestyle counseling session at baseline providing individualized dietary advice and physical activity recommendations based on ICMR national guidelines for Asian Indians, along with educational materials and follow-up assessments at 6 and 12 months.
Behavioral: Supervised Progressive Resistance Training · Behavioral: Standard Lifestyle Advice
12-month supervised progressive resistance training program, 3 sessions per week (60 min/session) at 70-80% 1-repetition maximum (1RM) featuring progressive overload reassessed every 8 weeks. Includes leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest press, overhead press, and abdominal crunches.
A single 60-minute structured lifestyle counseling session at baseline providing individualized dietary and physical activity advice according to ICMR consensus guidelines for Asian Indians, supplemented with written educational materials.
Percentage change in total lean body mass
Percentage change in total lean body mass (LBM) from baseline to 6 and 12 months measured by DEXA, comparing the resistance training and control groups and assessing differences between High-Ratio and Low-Ratio MSTN/FST strata.
Time frame: Baseline, 6 months, 12 months
Change in Serum Myostatin Concentration
Change in serum myostatin levels quantified in duplicate via validated sandwich ELISA (intra-assay CV \< 8%, inter-assay CV \< 10%).
Time frame: Baseline, 12 months
Change in Serum Follistatin Concentration
Change in serum follistatin levels quantified in duplicate via validated sandwich ELISA
Time frame: Baseline, 12 months
Change in Serum Myostatin/Follistatin (MSTN/FST) Ratio
Integrated dynamic index of anabolic-catabolic balance calculated as serum myostatin (pg/mL) divided by serum follistatin (pg/mL).
Time frame: Baseline, 12 months
Change in PBMC MSTN mRNA Expression
Relative gene expression of myostatin mRNA isolated from Peripheral Blood Mononuclear Cells (PBMCs) and measured via real-time quantitative PCR using the Livak 2 -ΔΔCT method normalized to GAPDH.
Time frame: Baseline, 12 months
Change in Systemic Inflammatory Markers
Quantification of circulating serum Interleukin-6 (IL-6; pg/mL), Tumor Necrosis Factor-alpha (TNF-α; pg/mL), and high-sensitivity C-Reactive Protein (hsCRP; mg/L) via high-sensitivity immunoassay methods.
Time frame: Baseline, 6 months, 12 months
Change in Skeletal Muscle Quality
Evaluation of muscle quality calculated as DEXA-derived muscle mass relative to strength, combined with ultrasound assessment of quadriceps muscle thickness and echo intensity.
Time frame: Baseline, 6 months, 12 months
Appendicular Lean Mass (ASMI)
Measured by DEXA (kg/m²)
Time frame: Baseline, 6-month, and 12-month.
Handgrip Strength
Measured using a calibrated hand dynamometer (kg)
Time frame: Baseline, 6-month, and 12-month.
Lower-Body Muscle Strength
Measured by 1-repetition maximum (1RM) in leg press (kg)
Time frame: Baseline, 6-month, and 12-month.
Gait Speed
Measured by 4-metre timed walk test (seconds or m/s)
Time frame: Baseline, 6-month, and 12-month.
Plan to share: Yes
Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.
Of 3,694 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 35 months is above that.
Counting every sponsor, half of 3,858 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diabetes Foundation, India